Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO)

R Soffietti, U Abacioglu, B Baumert, SE Combs… - Neuro …, 2017 - academic.oup.com
The management of patients with brain metastases has become a major issue due to the
increasing frequency and complexity of the diagnostic and therapeutic approaches. In 2014 …

Emerging treatment paradigms for EGFR-mutant lung cancers progressing on osimertinib: a review

AJ Piper-Vallillo, LV Sequist… - Journal of Clinical …, 2020 - ascopubs.org
Since its approval in April 2018, osimertinib has been widely adopted as first-line therapy for
patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC). Understanding …

Management of brain metastases in tyrosine kinase inhibitor–naïve epidermal growth factor receptor–mutant non–small-cell lung cancer: a retrospective multi …

WJ Magnuson, NH Lester-Coll, AJ Wu… - Journal of clinical …, 2017 - ascopubs.org
Purpose Stereotactic radiosurgery (SRS), whole-brain radiotherapy (WBRT), and epidermal
growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are treatment options for …

The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer

S Peters, C Bexelius, V Munk, N Leighl - Cancer treatment reviews, 2016 - Elsevier
This systematic review aims to improve understanding of the burden of disease associated
with brain metastases from non-small-cell lung cancer (NSCLC) in terms of survival, quality …

[HTML][HTML] The international association for the study of lung cancer consensus statement on optimizing management of EGFR Mutation–Positive Non–Small cell lung …

DSW Tan, SS Yom, MS Tsao, HI Pass, K Kelly… - Journal of Thoracic …, 2016 - Elsevier
Mutations in the epidermal growth factor receptor gene (EGFR) represent one of the most
frequent “actionable” alterations in non–small cell lung cancer (NSCLC). Typified by high …

[HTML][HTML] EGFR TKIs plus WBRT demonstrated no survival benefit other than that of TKIs alone in patients with NSCLC and EGFR mutation and brain metastases

T Jiang, C Su, X Li, C Zhao, F Zhou, S Ren… - Journal of Thoracic …, 2016 - Elsevier
Introduction Whether EGFR tyrosine kinase inhibitors (TKIs) plus whole brain radiation
therapy (WBRT) provide a better survival benefit than EGFR TKIs alone remains …

[HTML][HTML] LncRNA SNHG15 regulates EGFR-TKI acquired resistance in lung adenocarcinoma through sponging miR-451 to upregulate MDR-1

J Huang, B Pan, G Xia, J Zhu, C Li, J Feng - Cell death & disease, 2020 - nature.com
Lung adenocarcinoma (LUAD) is the main component of non-small-cell lung cancer
(NSCLC) and causes a great health concern globally. The top priority of LUAD treatment is …

[HTML][HTML] Management of brain metastases in epidermal growth factor receptor mutant non-small-cell lung cancer

WJ Kelly, NJ Shah, DS Subramaniam - Frontiers in oncology, 2018 - frontiersin.org
Lung cancer remains a leading cause of mortality with 1.69 million deaths worldwide.
Activating mutations in epidermal growth factor receptor (EGFR), predominantly exon 19 …

[HTML][HTML] Brain metastases in oncogene-addicted non-small cell lung cancer patients: incidence and treatment

J Remon, B Besse - Frontiers in Oncology, 2018 - frontiersin.org
Brain metastases (BM) are common in non-small cell lung cancer patients including in
molecularly selected populations, such as EGFR-mutant and ALK-rearranged tumors. They …

Management of brain metastases in lung cancer: evolving roles for radiation and systemic treatment in the era of targeted and immune therapies

NJ Myall, H Yu, SG Soltys, HA Wakelee… - Neuro-Oncology …, 2021 - academic.oup.com
Brain metastases are a common occurrence in both non-small cell and small cell lung
cancer with the potential to affect quality of life and prognosis. Due to concerns about the …